弥漫型与肠型早期胃癌患者淋巴结转移率和生存率相当:一项大型人群研究
基于监测、流行病学和最终结果(SEER)数据库纳入5593例手术切除的早期胃癌(肠型4376例、弥漫型1217例),多因素分析未发现Lauren分型与淋巴结转移相关(OR 0.93,95%CI 0.70-1.24,P=0.62),弥漫型与肠型预后相似(HR 0.95,95%CI 0.77-1.18,P=0.66;SHR 0.99,95%CI 0.80-1.22,P=0.926),倾向评分匹配后结果一致。
要点
- 多因素校正后Lauren分型与淋巴结转移无显著关联(OR 0.93,95%CI 0.70-1.24,P=0.62)。
- 弥漫型与肠型早期胃癌预后相似(HR 0.95,95%CI 0.77-1.18,P=0.66)。
- 选择内镜切除替代手术时应谨慎解读,因治疗选择取决于淋巴血管侵犯风险而非淋巴结转移率或预后。
核心结论
- 弥漫型早期胃癌的淋巴结转移风险和预后可能与肠型相当。
- 选择内镜切除替代手术时应谨慎解读这些结果,因为早期胃癌的治疗选择取决于淋巴血管侵犯风险而非淋巴结转移率或预后。
研究设计与样本
- 基于监测、流行病学和最终结果(SEER)数据库识别所有手术切除、组织学诊断为肠型或弥漫型早期胃癌的患者。
- 共纳入5593例早期胃癌,其中肠型4376例、弥漫型1217例。
- 采用多因素logistic回归、多因素Cox回归、多因素竞争风险模型和倾向评分匹配分析Lauren分型与淋巴结转移或预后的关联。
- 倾向评分匹配后733例弥漫型与733例肠型配对。
主要发现
- 校正其他危险因素后,Lauren分型与淋巴结转移无正相关(OR 0.93,95%CI 0.70-1.24,P=0.62)。
- 多因素Cox回归显示弥漫型与肠型预后相似(HR 0.95,95%CI 0.77-1.18,P=0.66)。
- 多因素竞争风险模型显示弥漫型与肠型预后相似(SHR 0.99,95%CI 0.80-1.22,P=0.926)。
- 倾向评分匹配后未发现Lauren分型与淋巴结转移相关(OR 0.98,95%CI 0.71-1.37,P=0.934)。
- 倾向评分匹配后单因素Cox回归(HR 0.98,95%CI 0.76-1.26,P=0.893)和单因素竞争风险模型(SHR 0.98,95%CI 0.76-1.26,P=0.893)均未发现Lauren分型与预后相关。
临床怎么用
- 作者认为,选择内镜切除替代手术时应谨慎解读这些结果,因为早期胃癌的治疗选择取决于淋巴血管侵犯风险而非淋巴结转移率或预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Limited evidence and contradictory results exist regarding the impact of Lauren type, namely diffuse and intestinal types, of lymph node metastasis (LNM) and prognosis for early gastric cancer (EGC). We aimed to compare LNM and prognosis between diffuse and intestinal type EGCs using comprehensive statistical analysis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify all patients with surgically resected, histologically diagnosed, intestinal or diffuse type EGC. Multivariate logistic regression, multivariate Cox regression, multivariate competing risk model, and propensity score matching were used to analyze association the Lauren type and LNM or prognosis. RESULTS: We identified 5593 EGCs from the SEER database, including 4376 intestinal types and 1217 diffuse types. No positive association was found between LNM and Lauren type (odds ratio, .93; 95% confidence interval [CI], .70-1.24; P = .62) after adjustment for other risk factors. Moreover, diffuse-type EGCs showed a similar prognosis to intestinal type EGCs in both multivariate Cox regression (HR [hazard ratio], .95; 95% CI, .77-1.18; P = .66) and the multivariate competing risk model (subdistribution HR [SHR], .99; 95% CI, .80-1.22; P = .926). Propensity score matching was used, and 733 diffuse types were matched with 733 intestinal types. We did not find any association between the Lauren type and LNM (odds ratio, .98; 95% CI, .71-1.37; P = .934) or prognosis in the univariate Cox regression (HR, .98; 95% CI, .76-1.26; P = .893) and univariate competing risk model (SHR, .98; 95% CI, .76-1.26; P = .893). CONCLUSIONS: Diffuse-type EGC may have a comparable risk of LNM and prognosis to intestinal-type EGC. Nevertheless, these results should be carefully interpreted with caution when choosing endoscopic resection instead of surgery, because the treatment choice for EGC depends on the risk of lymphovascular invasion rather than LNM rate or prognosis.
引用
- Li ZY, Zhang QW, Teng LM, et al. Comparable rates of lymph node metastasis and survival between diffuse type and intestinal type early gastric cancer patients: a large population-based study. Gastrointest Endosc. 2019. PMID: 30885598. doi:10.1016/j.gie.2019.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。